-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 29, Roche China announced that its innovative flu drug Sufuda® (English trade name: Xofluza®, Chinese generic name: Mabaloxavir) has been formally approved by the China National Medical Products Administration for the treatment of 12 years of age and The above acute uncomplicated influenza patients include those who are at high risk of influenza complications.
Influenza is a common acute respiratory infectious disease with serious consequences.
Mabaloxavir is an innovative cap-shaped structure-dependent endonuclease inhibitor.